Global Blood Therapeutics (GBT) was downgraded to a Hold Rating at Stifel Nicolaus
TipRanksAug 11, 2022 22:10 ET
Global Blood Therapeutics (GBT) was downgraded to a Hold Rating at SVB Securities
TipRanksAug 9, 2022 08:45 ET
Global Blood Therapeutics Downgraded by RBC to Sector Perform From Outperform, Price Target Raised to $68.50 From $60 Amid Pfizer Deal
MT NewswiresAug 9, 2022 08:30 ET
RBC Capital Downgrades Global Blood Therapeutics to Sector Perform, Raises Price Target to $68.5
Benzinga Real-time NewsAug 9, 2022 07:28 ET
Global Blood Therapeutics Price Target Raised to $68.50/Share From $66.00 by Wells Fargo
Dow JonesAug 9, 2022 07:20 ET
Global Blood Therapeutics Cut to Equal-Weight From Overweight by Wells Fargo
Dow JonesAug 9, 2022 07:20 ET
Global Blood Therapeutics Cut to Market Perform From Outperform by SVB Leerink
Dow JonesAug 9, 2022 06:47 ET
Global Blood Therapeutics Price Target Announced at $68.50/Share by SVB Leerink
Dow JonesAug 9, 2022 06:47 ET
SVB Leerink Downgrades Global Blood Therapeutics to Market Perform, Announces $68.5 Price Target
Benzinga Real-time NewsAug 9, 2022 06:38 ET
Cowen Downgrades Global Blood Therapeutics to Market Perform From Outperform, Adjusts Price Target to $68.50 From $67
MT NewswiresAug 9, 2022 05:36 ET
Global Blood Therapeutics Price Target Cut to $68.50/Share From $75.00 by Cantor Fitzgerald
Dow JonesAug 9, 2022 05:10 ET
Global Blood Therapeutics Cut to Neutral From Overweight by Cantor Fitzgerald
Dow JonesAug 9, 2022 05:10 ET
Global Blood Therapeutics Cut to Market Perform From Outperform by Cowen & Co.
Dow JonesAug 9, 2022 05:07 ET
Global Blood Therapeutics Price Target Raised to $68.50/Share From $67.00 by Cowen & Co.
Dow JonesAug 9, 2022 05:07 ET
Cantor Fitzgerald Downgrades Global Blood Therapeutics to Neutral, Lowers Price Target to $68.5
Benzinga Real-time NewsAug 9, 2022 05:00 ET
Global Blood Therapeutics analyst ratings
Benzinga Analyst RatingsAug 9, 2022 04:58 ET
Cowen & Co. Downgrades Global Blood Therapeutics to Market Perform, Raises Price Target to $68.5
Benzinga Real-time NewsAug 9, 2022 04:58 ET
Global Blood Therapeutics Cut to Neutral From Outperform by Wedbush
Dow JonesAug 8, 2022 13:46 ET
Global Blood Therapeutics analyst ratings
Benzinga Analyst RatingsAug 8, 2022 13:36 ET
Analysts Are Neutral on Top Healthcare Stocks: Global Blood Therapeutics (GBT), Cerevel Therapeutics Holdings (CERE)
TipRanksAug 8, 2022 13:05 ET
No Data
No Data